Symbols

BLFS

BioLife Solutions·NASDAQ

--(--)

BLFS fundamentals

BLFS Q4 2025 Earnings

BioLife Solutions (BLFS) released its earnings on Feb 26, 2026: revenue was 24.76M (YoY +9.03%), beat estimates; EPS was 0.22 (YoY +650.00%), beat estimates.

Revenue / YoY

24.76M

+9.03%

EPS / YoY

0.22

+650.00%

Report date

Feb 26, 2026

BLFS Earnings Call Summary for Q4,2025

Revenue Growth: 29% YoY to $96 million in 2025, driven by biopreservation media (BPM) with 85% Q4 contribution.
Strategic Expansion: New QKine partnership for cytokines and cross-selling initiative targeting 3x revenue per patient dose.
2026 Guidance: $112-115 million revenue (17-20% growth), first GAAP net income, and 2-3ppt margin improvement from resolved bag yield issues.
CGT Market Leadership: 70% share in Phase III+ trials, embedded in 16 approved therapies, and 250+ trials.
Operational Focus: ERP implementation and CryoCase adoption to reduce costs and improve margins in 2026.

Earnings

EPS

Revenue

Revenue & Expenses

BLFS has released its 2025 Q4 earnings report, with revenue of 18.79M, reflecting a YoY change of 24.34%, and net profit of 11.07M, showing a YoY change of -11.15%. The Sankey diagram below clearly presents BLFS's revenue sources and cost distribution.

Key Indicators

BioLife Solutions (BLFS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

BioLife Solutions (BLFS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

BioLife Solutions (BLFS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

BioLife Solutions (BLFS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown